NDA 220415 · Abbvie
Juvmo
Tavapadon · Oral
NovelCDER novel approval, Sep 25, 2026: To treat Parkinson's disease in adults
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Sep 25, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
4 Phase 3, 0 recruiting
FAERS reports
1
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
JUVMO is indicated for the treatment of Parkinson’s disease (PD) in adults. JUVMO is a non-ergot dopamine agonist indicated for the treatment of Parkinson’s disease in adults. ( 1 )
Mechanism: Tavapadon is a selective partial agonist at the dopamine D1 and D5 receptor subtypes (D 1 /D 5 ).
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
5 products under this application
- JUVMO · TAVAPADON 15MG · TABLET, ORAL · Prescription
- JUVMO · TAVAPADON 5MG · TABLET, ORAL · Prescription
- JUVMO · TAVAPADON 15MG · TABLET, ORAL · Prescription
- JUVMO · TAVAPADON 10MG · TABLET, ORAL · Prescription
- JUVMO (COPACKAGED) · TAVAPADON 0.25MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tavapadon" as an intervention, any sponsor and status, largest first.
- Open-label Trial in Parkinson's Disease (PD)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04760769 · 992 participants · Start Feb 24, 2021 · Primary completion Dec 1, 2025
Drug: Tavapadon · For: Parkinson Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 140 sites in all
- Fixed-Dose Trial in Early Parkinson's Disease (PD)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04201093 · 529 participants · Start Dec 13, 2019 · Primary completion Jun 28, 2024
Drug: Tavapadon; Placebo and 1 more · For: Parkinson Disease
Sites: Birmingham, Alabama; Little Rock, Arkansas; Fountain Valley, California · 77 sites in all
- Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04542499 · 507 participants · Start Sep 23, 2020 · Primary completion Jan 29, 2024
Drug: Tavapadon; Placebo · For: Parkinson Disease
Sites: Phoenix, Arizona; Little Rock, Arkansas; Fountain Valley, California · 146 sites in all
- Flexible-Dose Trial in Early Parkinson's Disease (PD)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04223193 · 304 participants · Start Jan 6, 2020 · Primary completion Oct 1, 2024
Drug: Tavapadon; Placebo · For: Parkinson Disease
Sites: Fresno, California; Boca Raton, Florida; Maitland, Florida · 53 sites in all
- A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult ParticipantsCompleted
AbbVieAbbVie (ABBV)
NCT06895356 · 83 participants · Start Mar 26, 2025 · Primary completion Jun 16, 2025
Drug: Tavapadon · For: Healthy Volunteer
Sites: Grayslake, Illinois
Cerevel Therapeutics, LLCIndustry
NCT05404529 · 32 participants · Start Apr 29, 2022 · Primary completion Jan 24, 2023
Drug: Tavapadon · For: Hepatic Impairment
Sites: Miami, Florida; Orlando, Florida; San Antonio, Texas
Cerevel Therapeutics, LLCIndustry
NCT05610189 · 25 participants · Start Dec 15, 2022 · Primary completion Dec 12, 2023
Drug: Tavapadon · For: Parkinson Disease
Sites: Los Alamitos, California; Hollywood, Florida; Orlando, Florida · 6 sites in all
Cerevel Therapeutics, LLCIndustry
NCT05581823 · 16 participants · Start Oct 19, 2022 · Primary completion Jan 27, 2023
Drug: Tavapadon; Carbamazepine · For: Parkinson Disease
Sites: Madison, Wisconsin
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anxiety disorder1
- cough1
- hallucination1
- panic attack1
- parkinson^s disease1
- therapeutic product effect incomplete1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.
Fernandez HH, Isaacson SH, Hauser RA, et al. · JAMA Neurol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial.
Pahwa R, Moro E, Espay AJ, et al. · JAMA Neurol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.
Fernandez HH, Bhatia P, Cloud L, et al. · Lancet Neurol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Short-term efficacy and safety of tavapadon for Parkinson's disease: An exploratory systematic review and meta-analysis of randomized clinical trials.
Campos TS, Pereira PS, Pires Marques ME, et al. · Parkinsonism Relat Disord 2026 · Systematic Review, Meta-Analysis
- "Efficacy, safety and certainty of evidence for selective D1/D5 dopamine receptor partial agonists in Parkinson's disease: a systematic review, meta-analysis and GRADE assessment".
Rashid AA, Mohammad A, Malik U, et al. · Neurol Sci 2026 · Systematic Review, Meta-Analysis
Sponsor: AbbVie · Also marketed as Juvmo (Copackaged)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.